According to Baihua Pharmaceutical's announcement, the first half of 2026 achieved operating income of 157 million yuan, a year-on-year decrease of 22.13%; net profit attributable to shareholders of listed companies was 147.603 million yuan, a year-on-year decrease of 42.08%; net profit after deducting non-recurring profit and loss was 12.1863 million yuan, a year-on-year decrease of 49.35%. Basic earnings per share were 0.0384 yuan, a year-on-year decrease of 42.08%. On June 9, 2026, the controlling shareholder of the company was changed to Jinhua Juxin Enterprise Management Partnership, and the actual controller was changed to the State-owned Assets Supervision and Administration Committee of the Jinhua Municipal People's Government. There were no profit distribution plans during the reporting period.

According to Baihua Pharmaceutical's announcement, the first half of 2026 achieved operating income of 157 million yuan, a year-on-year decrease of 22.13%; net profit attributable to shareholders of listed companies was 147.603 million yuan, a year-on-year decrease of 42.08%; net profit after deducting non-recurring profit and loss was 12.1863 million yuan, a year-on-year decrease of 49.35%. Basic earnings per share were 0.0384 yuan, a year-on-year decrease of 42.08%. On June 9, 2026, the controlling shareholder of the company was changed to Jinhua Juxin Enterprise Management Partnership, and the actual controller was changed to the State-owned Assets Supervision and Administration Committee of the Jinhua Municipal People's Government. There were no profit distribution plans during the reporting period.